HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.

Key PointsOne analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per share. https://www.nasdaq.com/articles/hsbc-thinks-abbvie-can-climb-315-heres-bull-case-plain-english